Trends in management of patients with new‐onset refractory status epilepticus ( NORSE ) from 2016 to 2023: An interim analysis
Epilepsia · 2024-08 · 65 (8)
DOI: 10.1111/epi.18014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, online erschienen am 05.06.2024. Verfasst von Aurelie Hanin und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Status Epilepticus, Diet, Ketogenic, Immunotherapy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Philippe Foundation, The Daniel Raymond Wong Neurology Research Fund, the NORSE/FIRES Research Fund at Yale.
Abstract (Originalsprache)
In response to the evolving treatment landscape for new‐onset refractory status epilepticus (NORSE) and the publication of consensus recommendations in 2022, we conducted a comparative analysis of NORSE management over time. Seventy‐seven patients were enrolled by 32 centers, from July 2016 to August 2023, in the NORSE/FIRES biorepository at Yale. Immunotherapy was administered to 88% of patients after a median of 3 days, with 52% receiving second‐line immunotherapy after a median of 12 days (anakinra 29%, rituximab 25%, and tocilizumab 19%). There was an increase in the use of second‐line immunotherapies (odds ratio [OR] = 1.4, 95% CI = 1.1–1.8) and ketogenic diet (OR = 1.8, 95% CI = 1.3–2.6) over time. Specifically, patients from 2022 to 2023 more frequently received second‐line immunotherapy (69% vs 40%; OR = 3.3; 95% CI = 1.3–8.9)—particularly anakinra (50% vs 13%; OR = 6.5; 95% CI = 2.3–21.0), and the ketogenic diet (OR = 6.8; 95% CI = 2.5–20.1)—than those before 2022. Among the 27 patients who received anakinra and/or tocilizumab, earlier administration after status epilepticus onset correlated with a shorter duration of status epilepticus ( ρ = .519, p = .005). Our findings indicate an evolution in NORSE management, emphasizing the increasing use of second‐line immunotherapies and the ketogenic diet. Future research will clarify the impact of these treatments and their timing on patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA.
- Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, INSERM, CNRS, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
- Epilepsy Unit, Department of Clinical Neurophysiology, DMU Neurosciences, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
- Section of Neurology, Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
- Department of Neurology, Weill Cornell Medicine, New York City, New York, USA.
- Wayne State University School of Medicine, Detroit, Michigan, USA.
ORCID-Profile: Aurelie Hanin, Anthony D Jimenez, Maysaa Merhi Basha, Ayush Batra, Krista Eschbach, Teneille E Gofton, Hiba A Haider, Mariel Kalkach Aparicio, Padmaja Kandula, Jong Woo Lee, Wazim Mohamed, Vineet Punia, Olga Taraschenko, Ji Yeoun Yoo, Sahar Zafar, Deepti Zutshi, Lawrence J Hirsch
Förderung
- Philippe Foundation
- The Daniel Raymond Wong Neurology Research Fund
- the NORSE/FIRES Research Fund at Yale
- Paratonnerre Association
- Swebilius Foundation
- Servier Institute
- Institut Servier
Zitieren
APA
Hanin, A., Jimenez, A. D., Gopaul, M., Asbell, H., Aydemir, S., Basha, M. M., Batra, A., Damien, C., Day, G. S., Eka, O., Eschbach, K., Fatima, S., Fields, M. C., Foreman, B., Gerard, E. E., Gofton, T. E., Haider, H. A., Hantus, S. T., Hocker, S., …, & Hirsch, L. J. (2024). Trends in management of patients with new‐onset refractory status epilepticus ( NORSE ) from 2016 to 2023: An interim analysis. Epilepsia, 65(8). https://doi.org/10.1111/epi.18014
Vancouver
Hanin A, Jimenez AD, Gopaul M, Asbell H, Aydemir S, Basha MM, et al. Trends in management of patients with new‐onset refractory status epilepticus ( NORSE ) from 2016 to 2023: An interim analysis. Epilepsia. 2024;65(8). doi:10.1111/epi.18014
BibTeX
@article{Hanin2024,
author = {Hanin, Aurelie and Jimenez, Anthony D and Gopaul, Margaret and Asbell, Hannah and Aydemir, Seyhmus and Basha, Maysaa Merhi and Batra, Ayush and Damien, Charlotte and Day, Gregory S and Eka, Onome and Eschbach, Krista and Fatima, Safoora and Fields, Madeline C and Foreman, Brandon and Gerard, Elizabeth E and Gofton, Teneille E and Haider, Hiba A and Hantus, Stephen T and Hocker, Sara and Jongeling, Amy and Kalkach Aparicio, Mariel and Kandula, Padmaja and Kang, Peter and Kazazian, Karnig and Kellogg, Marissa A and Kim, Minjee and Lee, Jong Woo and Marcuse, Lara V and McGraw, Christopher M and Mohamed, Wazim and Orozco, Janet and Pimentel, Cederic M and Punia, Vineet and Ramirez, Alexandra M and Steriade, Claude and Struck, Aaron F and Taraschenko, Olga and Treister, Andrew K and Wainwright, Mark S and Yoo, Ji Yeoun and Zafar, Sahar and Zhou, Daniel J and Zutshi, Deepti and Gaspard, Nicolas and Hirsch, Lawrence J},
title = {Trends in management of patients with new‐onset refractory status epilepticus ( NORSE ) from 2016 to 2023: An interim analysis},
journal = {Epilepsia},
year = {2024},
volume = {65},
number = {8},
doi = {10.1111/epi.18014}
}
EUVIMED